|
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We provide evidence of clinical benefit of afatinib in a 50-year-old Asian woman with HER2-mutant NSCLC who previously failed cytotoxic chemotherapy and gefitinib treatment.
|
29215816 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
CLINVAR |
Lung adenocarcinoma harboring mutations in the ERBB2 kinase domain.
|
16825508 |
2006 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Here, we performed mutational analysis of the ERBB2 kinase domain by polymerase chain reaction-single strand conformation polymorphism assay in 114 non-adenocarcinoma type non-small cell lung cancers (NSCLCs) tissue samples, including 100 squamous cell carcinomas, three adenosquamous carcinomas and 11 large cell carcinomas.
|
16029927 |
2006 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Non-small cell lung cancer (NSCLC) patients with tumors harboring these mutations seldom achieve clinical responses to dacomitinib and afatinib, two covalent quinazoline-based inhibitors of EGFR or HER2, respectively.
|
28363995 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to investigate the role of p95HER2 according to HER2 gene copy number (GCN) and HER2 mutation in non-small cell lung cancer (NSCLC).
|
22307009 |
2012 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Among the 323 patients with NSCLC (60.1% female; median age, 65 years [range, 33-93 years]), therapeutically targetable mutations were detected in EGFR, ALK, MET, BRCA1, ROS1, RET, ERBB2, or BRAF for 113 (35.0%) overall.
|
30325992 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In addition, 4% of non-small cell lung carcinomas were shown to have ERBB2 mutations in the kinase domain.
|
17150109 |
2006 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Most ROS1-rearranged NSCLCs had no concurrent mutation, whereas 73% of discordant cases harboured genetic aberrations, including EGFR and ERBB2.
|
29464758 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
HER2 gene copy numbers per cell were evaluated by fluorescent in situ hybridization (FISH) in 102 NSCLC patients treated with gefitinib, and previously evaluated for EGFR status by FISH, immunohistochemistry, and presence of mutations.
|
16051952 |
2005 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Considering that osimertinib can lead to enhanced HER-2 expression on cell surface and HER-2 overexpression is a mechanism of resistance to osimertinib, this study was addressed to investigate the potential of combining osimertinib with trastuzumab emtansine (T-DM1) in order to improve the efficacy of osimertinib and delay or overcome resistance in NSCLC cell lines with EGFR activating mutation and with T790M mutation or HER-2 amplification.
|
29202823 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
However, little is known about the benefit of HER2-targeted therapy for NSCLCs harboring HER2 alterations.
|
26545934 |
2016 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncology molecular testing: BRAF V600E for vemurafenib in melanoma; EML4-ALK for crizotinib and EGFR for erlotinib and gefitinib in non-small-cell lung cancer; KRAS against the use of cetuximab and panitumumab in colorectal cancer; ERBB2 (HER2/neu) for trastuzumab in breast cancer; BCR-ABL for tyrosine kinase inhibitors in chronic myeloid leukemia; and PML/RARα for all-trans-retinoic acid and arsenic trioxide treatment for acute promyelocytic leukemia.
|
22845480 |
2012 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
CLINVAR |
Lung cancer: intragenic ERBB2 kinase mutations in tumours.
|
15457249 |
2004 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The targeted therapies dabrafenib and neratinib are being tested separately in subsets of patients with BRAF- and HER2-mutant non-small cell lung cancer.
|
25477108 |
2014 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We have also investigated erbB2 mutation status in 27 surgically treated NSCLC cases followed by treatment with gefitinib from Kinki-chuo Chest Medical Center.
|
16003726 |
2006 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
CLINVAR |
Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.
|
15753357 |
2005 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Patients with advanced NSCLC(N = 1714) initially underwent testing for EGFR, KRAS, BRAF mutations and ALK, ROS1 rearrangements, and negative cases were then assessed for HER2 mutations using the method of amplification refractory mutation system(ARMS).
|
29587667 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
To assess the role of various epidermal growth factor receptor (EGFR) mutations and HER2/3 protein expression as predictive markers of responsiveness to gefitinib therapy in Chinese patients with advanced non-small cell lung cancer (NSCLC).
|
19020901 |
2009 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
ERBB2 and MET alterations include both activating mutations and gene amplifications, detection of which relies on molecular methods with a minimal role for IHC in NSCLC.
|
30188361 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
HER2 TMD mutations (V659 and G660) are found in other non-NSCLC malignancies, and analogous TMD mutations are also found in EGFR, HER3, and HER4.
|
27903463 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The authors evaluated surgically resected NSCLC tumors for EGFR (exons 18-21) and KRAS (codons 12-13) mutations and immunohistochemistry (EGFR, phosphorylated-EGFR, and HER2/Neu), and correlated results with clinical outcome and patient and disease features.
|
17409862 |
2006 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Responses were noted in patients with HER2-amplified breast cancer resistant to trastuzumab, HER2-mutant non-small-cell lung cancer, and tumor types without identified mutations in the HER-PI3K-mTOR pathway.
|
24323026 |
2014 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Finally, we briefly comment the available clinical data of dacomitinib in HER2-mutant NSCLC patients.
|
28424775 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The major eligibility criteria are as follows: age ≥ 20 years, pathologically diagnosed NSCLC with documented HER2 positivity (immunohistochemistry 3+, both immunohistochemistry 2+ and fluorescence in situ hybridization positive, or exon 20 insertion mutation), and previous chemotherapy.
|
27497829 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
FISH or CISH analysis of EGFR and HER2 genes was done on 42 small samples derived from NSCLC patients treated with gefitinib.
|
17406029 |
2007 |